POTSDAM, NY  / September 6, 2022 / Lento Bio, Inc., a preclinical pharmaceutical company developing small-molecule therapeutics to restore ocular lens flexibility and near-vision in presbyopia patients, announced today they have raised $680,000 in funding during their recent oversubscribed seed round. Ichor Life Sciences is the lead investor for the round, providing $400,000 in funding to Lento Bio.

Lento Bio is an Ichor portfolio company developing small-molecule therapeutic treatments for degenerative aging disorders, focused initially on developing AGE-breaking therapeutic eyedrops for presbyopia. Lento Bio was founded in 2022 and is headquartered in Potsdam, N.Y. For more information go to lentobio.com.

https://lentobio.com/

Therapeutics

Lento Bio Raises $680,000 In Oversubscribed Seed Round Led By Ichor Life Sciences

Description

Company Information

Funding Insights

Related People

Lento Bio Raises $680,000 In Oversubscribed Seed Round Led By Ichor Life Sciences

Description

.css-1v6jzuu{--tw-text-opacity:1;color:rgba(75, 85, 99, var(--tw-text-opacity));}Company Information

Funding Insights

Related People

Company Information